Genotype-guided dosing of warfarin through modeling and simulation.

Area of Science:

• Pharmacogenomics
• Pharmacokinetics/Pharmacodynamics
• Computational Biology

Background:

• Current warfarin dosing algorithms show performance disparities in non-white populations due to biased development data.
• Existing genotype-guided algorithms fail to fully address dynamic dose/response relationships, limiting their utility during warfarin initiation.
• VKORC1 and CYP2C9 genetic variants significantly influence warfarin response, increasing risks of over-anticoagulation.

Purpose of the Study:

• To develop a novel warfarin dosing nomogram applicable across diverse genotypes and ethnicities.
• To address limitations of current algorithms by incorporating ethnic diversity and dynamic dose/response modeling.
• To leverage a kinetic/pharmacodynamic (K/PD) model for improved warfarin dosing strategies.

Main Methods:

• Utilized a previously published kinetic/pharmacodynamic (K/PD) model.
• Developed a warfarin dosing nomogram incorporating data from ethnically diverse and European patients.
• Accounted for differential dose/response behaviors influenced by VKORC1 and CYP2C9 genotypes.

Main Results:

• Simulations indicate the nomogram enables effective attainment of therapeutic international normalized ratio (INR) within one week for diverse populations.
• The proposed nomogram maintains uniform INR response profiles across different genotypes.
• In silico clinical trial simulations suggest feasibility for refining the nomogram and exploring outcomes.

Conclusions:

• The novel K/PD model-based nomogram offers a promising approach for equitable and effective warfarin dosing across diverse patient groups.
• This strategy addresses ethnic and genetic disparities in current genotype-guided warfarin dosing.
• In silico modeling provides a valuable tool for optimizing dosing nomograms before clinical trials.